Technical peptide guides, head-to-head comparisons, and buyer's-checklist writeups. Written for researchers evaluating compounds, sources, and testing documentation.
Research Clusters
Three clusters map the current novel-compound landscape — the triple agonist, the targeted-adipocyte investigational peptide, and the head-to-head comparison. All content is for laboratory research use only.
Triple Agonist & Sourcing
UBT251 is a triple-receptor agonist peptide engineered to engage the GLP-1, GIP, and glucagon receptor classes in a single backbone. The cluster covers the published structural profile, lyophilized handling notes, and what a lab should verify before sourcing: sequence identity, LC-MS and HPLC lot documentation, endotoxin results, and USA manufacture. PX1 supplies UBT251 as 10mg and 20mg research vials with lot-tracked certificates in the COA archive.
Targeted Adipocyte Apoptosis
CBL-514 is an investigational peptide studied in preclinical models for selective adipocyte-targeted apoptosis pathways. The cluster gathers the mechanism literature, formulation and reconstitution notes, and the documentation set a research team should expect with any lot: identity, purity, and sterility results from an accredited laboratory. PX1 supplies CBL-514 as a 10mg research vial, lot-tracked and independently tested.
UBT-251 vs Retatrutide
A side-by-side research comparison of UBT251 and Retatrutide: receptor-class coverage, backbone design, molecular profile, and supplied format. The comparison also maps where the two compounds differ as research materials — sourcing depth, lot documentation, and published handling data — so a lab can evaluate both strictly as research peptides.
GHRH analogs vs GHRPs, DAC vs no-DAC, and why sermorelin + CJC-1295 + ipamorelin get stacked together in research protocols.
Read MoreMOTS-c is a mitochondrially-encoded 16-residue peptide that activates AMPK. Mechanism, animal findings, and comparison with SS-31.
Read MoreBPC-157 is a 15-residue synthetic peptide with 200+ preclinical publications on tissue repair and GI integrity. Mechanism and handling.
Read More5-Amino-1MQ inhibits NNMT — a metabolic brake on the NAD+ salvage pathway. Mechanism, animal data, and purity considerations.
Read MoreNAD+, NMN, NR — precursor pathways, sirtuin activation, handling considerations, and what purity documentation to demand.
Read MoreSS-31 is a mitochondria-targeted tetrapeptide that binds cardiolipin. Structure, MMPOWER trial data, and purity considerations for research.
Read MoreTwo-peptide combination vs single triple-agonist. Efficacy magnitude, mechanism, adverse events, and how to evaluate purity for both.
Read MoreCagriSema combines cagrilintide (amylin analog) with PX1-S (GLP-1). REDEFINE Phase 3 data, mechanism, and handling for research.
Read MoreSURPASS-2 head-to-head data, receptor pharmacology, dosing schedules, and where PX13-R fits in the incretin research landscape.
Read More
